P 22077
Based on 24 publication(s) in Google Scholar
P 22077 is a cell-permeable ubiquitin-specific protease 7 (USP7) inhibitor with an EC50 of 8.01 μM. P 22077 also inhibits USP47 with an EC50 of 8.74 μM.
For research use only. We do not sell to patients.
- Purity: 98.42%
- CAS No.: 1247819-59-5
- Formula: C12H7F2NO3S2
- Molecular Weight:315.32
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Ubiquitination Compound Library
HY-L050
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Protease Inhibitor Library
HY-L147
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) P 22077
More- Nat Commun. 2025 May 16;16(1):4564. [Abstract]
- Nat Commun. 2025 Feb 27;16(1):2039. [Abstract]
- Nat Commun. 2023 Feb 9;14(1):731. [Abstract]
- Nat Commun. 2022 Mar 31;13(1):1700. [Abstract]
- Nat Chem Biol. 2017 Dec;13(12):1207-1215. [Abstract]
- J Immunother Cancer. 2026 Jan 14;14(1):e013498. [Abstract]
- Cell Death Dis. 2025 Dec 24. [Abstract]
- Cell Death Dis. 2024 Oct 15;15(10):749. [Abstract]
- Cell Death Dis. 2022 Aug 10;13(8):698. [Abstract]
- Haematologica. 2019 Nov;104(11):2178-2187. [Abstract]
- Biomed Pharmacother. 2023 Jun:162:114700. [Abstract]
- Oncogene. 2025 May;44(18):1245-1258. [Abstract]
- PLoS Biol. 2026 Mar 12;24(3):e3003698. [Abstract]
- Cell Chem Biol. 2021 Jun 17;28(6):855-865.e9. [Abstract]
- Cell Death Discov. 2025 Apr 17;11(1):183. [Abstract]
- J Med Chem. 2022 Oct 27;65(20):13645-13659. [Abstract]
- Br J Cancer. 2020 Apr;122(8):1175-1184. [Abstract]
- J Mol Biol. 2023 Dec 1;435(23):168316. [Abstract]
- Mol Neurobiol. 2022 Aug;59(8):5207-5221. [Abstract]
- Med Oncol. 2022 Feb 12;39(5):55. [Abstract]
- Toxicol Appl Pharmacol. 2024 Aug 20:117075. [Abstract]
- Anim Cells Syst. 2024 May 11;28(1):237-250. [Abstract]
- J Leukoc Biol. 2025 Sep 1;117(9):qiaf129. [Abstract]
- J Oncol. 2022 Jun 23;2022:8724933. [Abstract]
Customer Validation & Images
-
WB
Biological Activity
EC50: 8.01 μM (USP7), 8.74 μM (USP47)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
8.82 μM
Compound: P22077
|
Antiproliferative activity against human HCT116 cells expressing wild type p53 assessed as decrease in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells expressing wild type p53 assessed as decrease in cell viability after 72 hrs by MTT assay
|
[PMID: 28108249] |
| Sf9 | IC50 |
8 μM
Compound: 4
|
Inhibition of recombinant USP7 expressed in Sf9 cells by Ub-CHOP reporter assay
Inhibition of recombinant USP7 expressed in Sf9 cells by Ub-CHOP reporter assay
|
[PMID: 24900381] |
P 22077 is an inhibitor of USP7 and DUB USP47, with EC50s of 8.01 μM and 8.74 μM, respectively. P 22077 (15-45 μM) inhibits a much smaller subset of DUBs. P 22077 (25 μM) causes DUBs inhibition in HEK293T cells[1]. P 22077 (0-20 μM) greatly reduces the cell viability of Neuroblastoma (NB) cells including IMR-32, NGP, CHLA-255, and SH-SY5Y cells but without NB-19 and SK-N-AS cells. P 22077 (10 μM) increases p53 activity and induces apoptosis in p53 wild-type and HDM2-expressing NB cells. P 22077 (5 μM) enhances the cytotoxic effect of Dox and VP-16 on NB cells, and enhances Dox- and VP-16-induced p53-mediated apoptosis[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1247819-59-5
-
Appearance Solid
-
Molecular Weight 315.32
-
Formula C12H7F2NO3S2
-
Color Light yellow to yellow
-
SMILES
CC(C1=CC([N+]([O-])=O)=C(SC2=CC=C(F)C=C2F)S1)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (24)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2025 May 16;16(1):4564. PMID: 40379682 -
Nat Commun
The adaptor protein AP-3β disassembles heat-induced stress granules via 19S regulatory particle in Arabidopsis. [Abstract]2025 Feb 27;16(1):2039. PMID: 40016204 -
Nat Commun
Angiotensin-converting enzyme inhibitor promotes angiogenesis through Sp1/Sp3-mediated inhibition of notch signaling in male mice. [Abstract]2023 Feb 9;14(1):731. PMID: 36759621 -
Nat Commun
USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy. [Abstract]2022 Mar 31;13(1):1700. PMID: 35361799 -
Nat Chem Biol
2017 Dec;13(12):1207-1215. PMID: 28967922
P 22077 purchased from MedChemExpress. Usage Cited in: Nat Chem Biol. 2017 Dec;13(12):1207-1215. [Abstract]
The effects of HBX19818 on FLT 3 expression in FLT 3-ITD-expressing Ba/F3 cells after 22 h of treatment. The effects of P22077 on FLT 3 levels in FLT 3-ITD-expressing Ba/F3 cells after 22 h of treatment.
-
J Immunother Cancer
CD47 destabilization via manipulating the SPOP-USP2 axis augments macrophage phagocytosis and cancer immunotherapy. [Abstract]2026 Jan 14;14(1):e013498. PMID: 41534899 -
Cell Death Dis
SPOP and HAUSP bidirectionally regulate LZTS2 ubiquitination to modulate the Wnt pathway. [Abstract]2025 Dec 24. PMID: 41436424 -
Cell Death Dis
USP7 depletion potentiates HIF2α degradation and inhibits clear cell renal cell carcinoma progression. [Abstract]2024 Oct 15;15(10):749. PMID: 39406703 -
Cell Death Dis
USP7 regulates the ERK1/2 signaling pathway through deubiquitinating Raf-1 in lung adenocarcinoma. [Abstract]2022 Aug 10;13(8):698. PMID: 35948545 -
Haematologica
Deubiquitylase USP7 regulates human terminal erythroid differentiation by stabilizing GATA1. [Abstract]2019 Nov;104(11):2178-2187. PMID: 30872372 -
Biomed Pharmacother
2023 Jun:162:114700. PMID: 37062218 -
Oncogene
Helicobacter pylori activates DOPEY1 to promote p53 degradation through the USP7/TRIP12 axis in gastric tumorigenesis. [Abstract]2025 May;44(18):1245-1258. PMID: 39939725 -
PLoS Biol
USP7 facilitates brain tumor survival upon glucose deprivation by regulating phosphofructokinase muscle-type nuclear translocation in mice. [Abstract]2026 Mar 12;24(3):e3003698. PMID: 41818193 -
Cell Chem Biol
Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2. [Abstract]2021 Jun 17;28(6):855-865.e9. PMID: 33979649 -
Cell Death Discov
USP7 promotes endothelial activation to aggravate sepsis-induced acute lung injury through PDK1/AKT/NF-κB signaling pathway. [Abstract]2025 Apr 17;11(1):183. PMID: 40246841 -
J Med Chem
Discovery of Potent OTUB1/USP8 Dual Inhibitors Targeting Proteostasis in Non-Small-Cell Lung Cancer. [Abstract]2022 Oct 27;65(20):13645-13659. PMID: 36221183 -
Br J Cancer
2020 Apr;122(8):1175-1184. PMID: 32015510 -
J Mol Biol
2023 Dec 1;435(23):168316. PMID: 37858708 -
Mol Neurobiol
LncRNA ZNF883-Mediated NLRP3 Inflammasome Activation and Epilepsy Development Involve USP47 Upregulation. [Abstract]2022 Aug;59(8):5207-5221. PMID: 35678979 -
Med Oncol
Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma. [Abstract]2022 Feb 12;39(5):55. PMID: 35150316 -
Toxicol Appl Pharmacol
Artesunate attenuates osteoarthritis in mice by promoting MTA1 transcription through a USP7/FoxO1 axis. [Abstract]2024 Aug 20:117075. PMID: 39173720 -
Anim Cells Syst
Blocking SLC7A11 attenuates the proliferation of esophageal squamous cell carcinoma cells. [Abstract]2024 May 11;28(1):237-250. PMID: 38741950 -
J Leukoc Biol
S100A9 promotes inflammasome-dependent autoinflammation by blocking the degradation of SYK tyrosine kinase. [Abstract]2025 Sep 1;117(9):qiaf129. PMID: 40966542 -
J Oncol
2022 Jun 23;2022:8724933. PMID: 35783158
Solvent & Solubility
DMSO : 50 mg/mL (158.57 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 5 mg/mL (15.86 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Recombinant full length USP7, USP2 core, USP5, JOSD2, DEN1, PLpro core, and SENP2 catalytic core are generated. Amino terminal His6 tagged USP4, USP8, USP28, UCH-L1, UCH-L3, UCH-L5, and MMP13 are expressed in Escherichia coli. N-terminal His6 tagged USP15, USP20, and USP47 are expressed in Sf9 cells. All the recombinant proteins are purified by chromatography. Amino terminal tagged His6 Ub-PLA2 (Ub-CHOP), SUMO3-PLA2 (SUMO3-CHOP), ISG15-PLA2 (ISG15-CHOP), NEDD8-PLA2 (NEDD8-CHOP), Ub-EKL (Ub-CHOP2), and free catalytically active PLA2 are prepared[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Cell viability assays are assessed using the Cell Counting Kit-8 (CCK-8, WST-8[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2 H-tetrazolium, monosodium salt]). Cells are seeded in 96-well flat-bottomed plates at the density of 1 × 104 per well. After 24 h of incubation at 37°C, increasing concentrations of P 22077, Dox, VP-16, or their combinations are added to the wells. Twenty-four hours later, 10 μL of CCK-8 is added into each well and after 1 h of incubation, the absorbance is measure at 450 nm using the microplate reader. Each experiment is performed in replicates of six. Background reading of media only is used to normalize the results[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
The orthotopic Neuroblastoma (NB) mouse model is used in the assay. Briefly, 1.5 × 106 human IMR-32, SH-SY5Y, or NGP cells with luciferase expression are surgically injected into the left renal capsule of 5-week-old female NCR nude mice. IMR-32, SH-SY5Y, and NGP-derived xenografts are allowed to grow for ~2-3 weeks before randomizing the mice into a control group and a P 22077 treatment group. Each group consists of three or six mice. Animals are treated with DMSO or P 22077 by intraperitoneal (i.p.) injection every day for 12, 14, or 21 days. At the end of the experiments, all mice are killed. Tumors and the right side control kidneys are resected, weighed, and photographed[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (596 KB)
- English - EN (596 KB)
- Français - FR (596 KB)
- Deutsch - DE (596 KB)
- Norwegian - NO (596 KB)
- Español - ES (596 KB)
- Swedish - SV (596 KB)
- Italian - IT (596 KB)
- Portuguese - PT (596 KB)
-
Handling Instructions (2659 KB)
References
[1]. Altun M, et al. Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem Biol. 2011 Nov 23;18(11):1401-12. [Content Brief]
[2]. Fan YH, et al. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell Death Dis. 2013 Oct 17;4:e867. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1714 mL | 15.8569 mL | 31.7138 mL | 79.2845 mL |
| 5 mM | 0.6343 mL | 3.1714 mL | 6.3428 mL | 15.8569 mL | |
| 10 mM | 0.3171 mL | 1.5857 mL | 3.1714 mL | 7.9285 mL | |
| 15 mM | 0.2114 mL | 1.0571 mL | 2.1143 mL | 5.2856 mL | |
| 20 mM | 0.1586 mL | 0.7928 mL | 1.5857 mL | 3.9642 mL | |
| 25 mM | 0.1269 mL | 0.6343 mL | 1.2686 mL | 3.1714 mL | |
| 30 mM | 0.1057 mL | 0.5286 mL | 1.0571 mL | 2.6428 mL | |
| 40 mM | 0.0793 mL | 0.3964 mL | 0.7928 mL | 1.9821 mL | |
| 50 mM | 0.0634 mL | 0.3171 mL | 0.6343 mL | 1.5857 mL | |
| 60 mM | 0.0529 mL | 0.2643 mL | 0.5286 mL | 1.3214 mL | |
| 80 mM | 0.0396 mL | 0.1982 mL | 0.3964 mL | 0.9911 mL | |
| 100 mM | 0.0317 mL | 0.1586 mL | 0.3171 mL | 0.7928 mL |
Powered by Bioz